Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
NCT02352844Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in solid tumor, sponsored by Washington University School of Medicine. Started Oct 2015; status: completed.
02
Drugs
everolimus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02352844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352844.